Xvivo Perfusion AB (XVIVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has a cash flow conversion efficiency ratio of 0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr63.49 Million ≈ $6.83 Million USD) by net assets (Skr2.20 Billion ≈ $236.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XVIVO stock market capitalisation for the company's overall valuation and market capitalisation.
Xvivo Perfusion AB - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xvivo Perfusion AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xvivo Perfusion AB ranked by their cash flow conversion efficiency. Explore Xvivo Perfusion AB cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SILEX Systems Ltd
AU:SLX
|
0.027x |
|
SK Securities Co Ltd Preference Shares
KO:001515
|
-0.132x |
|
FARO Technologies Inc
NASDAQ:FARO
|
0.019x |
|
Sichuan Yimikang Environmental Tech Co Ltd
SHE:300249
|
0.053x |
|
SP Group A/S
CO:SPG
|
0.085x |
|
Entero Healthcare Solutions Ltd.
NSE:ENTERO
|
-0.033x |
|
Nuveen Select Tax-Free Income Portfolio
NYSE:NXP
|
-0.002x |
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Xvivo Perfusion AB (2011–2025)
The table below shows the annual cash flow conversion efficiency of Xvivo Perfusion AB from 2011 to 2025. View today's stock price for Xvivo Perfusion AB for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr2.11 Billion ≈ $227.44 Million |
Skr101.07 Million ≈ $10.88 Million |
0.048x | -7.33% |
| 2024-12-31 | Skr2.16 Billion ≈ $232.10 Million |
Skr111.29 Million ≈ $11.98 Million |
0.052x | +116.83% |
| 2023-12-31 | Skr1.95 Billion ≈ $209.32 Million |
Skr46.29 Million ≈ $4.98 Million |
0.024x | +22.18% |
| 2022-12-31 | Skr1.43 Billion ≈ $153.91 Million |
Skr27.86 Million ≈ $3.00 Million |
0.019x | +307.63% |
| 2021-12-31 | Skr1.29 Billion ≈ $138.33 Million |
Skr-12.06 Million ≈ $-1.30 Million |
-0.009x | +22.87% |
| 2020-12-31 | Skr1.01 Billion ≈ $108.53 Million |
Skr-12.27 Million ≈ $-1.32 Million |
-0.012x | -123.81% |
| 2019-12-31 | Skr577.52 Million ≈ $62.15 Million |
Skr29.50 Million ≈ $3.18 Million |
0.051x | +16.87% |
| 2018-12-31 | Skr540.48 Million ≈ $58.16 Million |
Skr23.63 Million ≈ $2.54 Million |
0.044x | -0.64% |
| 2017-12-31 | Skr504.33 Million ≈ $54.27 Million |
Skr22.19 Million ≈ $2.39 Million |
0.044x | +10.93% |
| 2016-12-31 | Skr316.41 Million ≈ $34.05 Million |
Skr12.55 Million ≈ $1.35 Million |
0.040x | -14.52% |
| 2015-12-31 | Skr184.87 Million ≈ $19.90 Million |
Skr8.58 Million ≈ $923.13K |
0.046x | +318.52% |
| 2014-12-31 | Skr176.18 Million ≈ $18.96 Million |
Skr-3.74 Million ≈ $-402.59K |
-0.021x | -115.24% |
| 2013-12-31 | Skr96.64 Million ≈ $10.40 Million |
Skr13.46 Million ≈ $1.45 Million |
0.139x | +641.01% |
| 2012-12-31 | Skr88.77 Million ≈ $9.55 Million |
Skr1.67 Million ≈ $179.61K |
0.019x | -98.42% |
| 2011-12-31 | Skr11.91 Million ≈ $1.28 Million |
Skr14.17 Million ≈ $1.52 Million |
1.190x | -- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more